Cantor Fitzgerald Reiterates “Neutral” Rating for ADMA Biologics (NASDAQ:ADMA)

ADMA Biologics (NASDAQ:ADMA)‘s stock had its “neutral” rating reaffirmed by equities research analysts at Cantor Fitzgerald in a research report issued on Thursday,Benzinga reports.

A number of other research firms also recently weighed in on ADMA. Wall Street Zen raised shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research note on Saturday, February 28th. Zacks Research raised shares of ADMA Biologics from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 2nd. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a report on Tuesday, December 23rd. Two equities research analysts have rated the stock with a Strong Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, ADMA Biologics presently has a consensus rating of “Buy” and an average target price of $32.00.

ADMA Biologics Price Performance

ADMA Biologics stock opened at $9.63 on Thursday. The business’s 50-day simple moving average is $15.95 and its 200 day simple moving average is $16.52. The company has a quick ratio of 3.74, a current ratio of 6.71 and a debt-to-equity ratio of 0.16. The stock has a market cap of $2.29 billion, a price-to-earnings ratio of 16.05 and a beta of 0.51. ADMA Biologics has a 12-month low of $8.62 and a 12-month high of $25.67.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share for the quarter, hitting the consensus estimate of $0.20. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.The firm had revenue of $139.16 million during the quarter, compared to analysts’ expectations of $139.80 million. During the same period in the previous year, the business posted $0.46 EPS. The company’s quarterly revenue was up 18.4% compared to the same quarter last year. As a group, research analysts anticipate that ADMA Biologics will post 0.51 earnings per share for the current year.

Insider Transactions at ADMA Biologics

In other news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the company’s stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $15.63, for a total value of $157,800.48. Following the completion of the sale, the chief operating officer directly owned 466,600 shares of the company’s stock, valued at $7,292,958. This represents a 2.12% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Steve Elms purchased 7,000 shares of the business’s stock in a transaction that occurred on Thursday, March 5th. The stock was purchased at an average price of $15.67 per share, for a total transaction of $109,690.00. Following the completion of the transaction, the director directly owned 2,038,730 shares in the company, valued at $31,946,899.10. This trade represents a 0.34% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 3.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On ADMA Biologics

Several large investors have recently bought and sold shares of ADMA. Thrivent Financial for Lutherans lifted its stake in ADMA Biologics by 24.9% in the 3rd quarter. Thrivent Financial for Lutherans now owns 4,141,840 shares of the biotechnology company’s stock valued at $60,719,000 after acquiring an additional 826,415 shares in the last quarter. Ranger Investment Management L.P. grew its stake in shares of ADMA Biologics by 49.1% during the 2nd quarter. Ranger Investment Management L.P. now owns 2,390,375 shares of the biotechnology company’s stock worth $43,529,000 after acquiring an additional 786,865 shares in the last quarter. Boothbay Fund Management LLC bought a new position in shares of ADMA Biologics during the 3rd quarter worth approximately $11,334,000. American Century Companies Inc. raised its holdings in shares of ADMA Biologics by 1.8% in the third quarter. American Century Companies Inc. now owns 4,695,923 shares of the biotechnology company’s stock valued at $68,842,000 after purchasing an additional 84,934 shares during the last quarter. Finally, WINTON GROUP Ltd lifted its position in shares of ADMA Biologics by 302.8% in the second quarter. WINTON GROUP Ltd now owns 272,817 shares of the biotechnology company’s stock worth $4,968,000 after purchasing an additional 205,094 shares in the last quarter. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics News Summary

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: ADMA was added to the Zacks Rank #1 (Strong Buy) list, which could attract buying interest and analyst attention. New Strong Buy Stocks for March 25th
• Positive Sentiment: Management and the Board publicly rejected the short‑seller report as misleading and said they are reviewing the assertions — a formal rebuttal can limit some downside if it calms investors or leads to clarifying disclosures. ADMA Biologics Addresses Misleading Short‑Seller Report
• Neutral Sentiment: Technical analysts note heavy selling has pushed ADMA into oversold territory and some see the stock set up for a rebound if selling abates and fundamentals hold. Down 27% in 4 Weeks — Turnaround Case
• Negative Sentiment: A detailed short‑seller report (Culper Research) prompted a sharp share decline and increased volatility; such reports can materially pressure price even if later disputed. Shares Plunge on Short‑Seller Allegations
• Negative Sentiment: Multiple law firms have opened securities‑fraud/shareholder investigations and issued alerts; active class‑action/claim activity increases legal and disclosure risk and can keep downward pressure on the stock. Securities‑Fraud Investigation Announced
• Negative Sentiment: Reported short interest jumped materially (recent filings show ~25.8M shares short, ~11% of float), creating added downside via short selling and raising the risk of continued volatility. ADMA Stock Slides — Facts Before You Trade

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.